Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions

Prostate Cancer

Interventions

DRUG

VT-464: given orally twice daily in 28-day cycles

Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose

DRUG

VT-464: given orally once daily in 28-day cycles

Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose

Trial Locations (1)

National Institutes of Health, National Cancer Institute, Bethesda